The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Lymphoblastic Lymphoma
Both
Lymphoblastic Lymphoma
Trial Information
The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD
regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment.
After achievement of response, patients either underwent hematopoietic stem cell
transplantation (HSCT) or consolidation with hyper-CVAD.
Inclusion Criteria:
- age over 18 at diagnosis
- Pathologically proven lymphoblastic lymphoma
Exclusion Criteria:
- proven HIV infection
- pretreatment with other regimens
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Outcome Measure:
Overall survival
Outcome Time Frame:
3-year
Safety Issue:
No
Authority:
Korea: Institutional Review Board
Study ID:
LBL-CISL-1
NCT ID:
NCT01813344
Start Date:
January 2012
Completion Date:
Related Keywords:
- Lymphoblastic Lymphoma
- Adult lymphoblastic lymphoma
- Hyper-CVAD
- first-line treatment
- Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Non-Hodgkin
Name | Location |
|---|
